Lavipharm Valuation

Is LAVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LAVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LAVI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LAVI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LAVI?

Key metric: As LAVI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LAVI. This is calculated by dividing LAVI's market cap by their current earnings.
What is LAVI's PE Ratio?
PE Ratio	16.9x
Earnings	€7.13m
Market Cap	€120.61m

LAVI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	20.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does LAVI's PE Ratio compare to its peers?

The above table shows the PE ratio for LAVI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16x
524280 Kopran	20.2x	n/a	₹10.7b
A000020 Dongwha Pharm.Co.Ltd	24.2x	n/a	₩184.3b
1777 SYN-TECH Chem. & Pharm	13.2x	n/a	NT$4.4b
ACMELAB ACME Laboratories	6.5x	n/a	৳15.7b
LAVI Lavipharm	16.9x	n/a	€120.6m

Price-To-Earnings vs Peers: LAVI is expensive based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (16.1x).

Price to Earnings Ratio vs Industry

How does LAVI's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: LAVI is good value based on its Price-To-Earnings Ratio (16.9x) compared to the European Pharmaceuticals industry average (20x).

Price to Earnings Ratio vs Fair Ratio

What is LAVI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LAVI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LAVI's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.